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Abstract
Background: Combination antimalarial therapy is recommended for the treatment of
uncomplicated falciparum malaria in Africa; however, some concerns about the safety and
tolerability of new regimens remain. This study compared the safety and tolerability of three
combination antimalarial regimens in a cohort of Ugandan children.
Methods: A longitudinal, single-blind, randomized clinical trial of children was conducted between
November 2004 and May 2007 in Kampala, Uganda. Upon diagnosis of the first episode of
uncomplicated malaria, participants were randomized to treatment with amodiaquine +
sulphadoxine-pyrimethamine (AQ+SP), artesunate + amodiaquine (AS+AQ), or artemether-
lumefantrine (AL). Once randomized, participants received the same regimen for all subsequent
episodes of uncomplicated malaria. Participants were actively monitored for adverse events for the
first 14 days after each treatment, and then passively followed until their next study medication
treatment, or withdrawal from study. Outcome measures included the risk of adverse events at 14
and 42 days after treatment.
Results: Of 601 enrolled children, 382 were diagnosed with at least one episode of uncomplicated
malaria and were treated with study medications. The median age at treatment was 6.3 years (range
1.1 – 12.3 years). At 14 days of follow-up, AQ+SP treatment was associated with a higher risk of
anorexia, weakness, and subjective fever than treatment with AL, and a higher risk of weakness,
and subjective fever than treatment with AS+AQ. Treatment with AL was associated with a higher
risk of elevated temperature. Repeated episodes of neutropaenia associated with AS+AQ were
detected in one participant. Considering only children less than five years, those who received
AQ+SP were at higher risk of developing moderate or severe anorexia and weakness than those
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treated with AL (anorexia: RR 3.82, 95% CI 1.59 – 9.17; weakness: RR 5.40, 95% CI 1.86 – 15.7),
or AS+AQ (anorexia: RR 2.10, 95% CI 1.04 – 4.23; weakness: RR 2.26, 95% CI 1.01 – 5.05).
Extending the analysis to 42 days of follow-up had little impact on the findings.
Conclusion: This study confirms the safety and tolerability of AS+AQ and AL in Ugandan children,
and suggests that AQ+SP is safe, but less well-tolerated, particularly in younger children. As newer
antimalarial regimens are deployed, collecting data on their safety and tolerability will be essential.
Trial registration: Current Controlled Trials Identifier ISRCTN37517549
Background
Combination antimalarial therapy is now advocated for
treatment of uncomplicated falciparum malaria in Africa
[1,2]. Of the five regimens currently recommended by the
World Health Organization (WHO) for treatment of falci-
parum malaria, two artemisinin-based combination ther-
apies (ACTs), artesunate + amodiaquine (AS+AQ) and
artemether-lumefantrine (AL), have been adopted by
most countries in sub-Saharan Africa [3]. A non-ACT reg-
imen, amodiaquine + sulphadoxine-pyrimethamine
(AQ+SP), is recommended as an alternative to ACT in
areas where both drugs remain effective. This regimen
benefits from its lower cost, and may be a good option for
parts of West Africa [4-6].
Although combination therapy is highly effective, some
concerns about the safety and tolerability of these regi-
mens remain [7]. Serious toxicity has been associated with
SP and AQ, particularly when used for long-term chemo-
prophylaxis, including severe cutaneous reactions with
SP, and neutropaenia and hepatotoxicity with AQ [8-10].
However, both drugs appear to be much safer when used
in short-term treatment regimens [11,12]. Artemisinin
derivatives are generally safe and well-tolerated, but there
are concerns about the potential for neurotoxicity and
reproductive toxicity [13-15]. Lumefantrine, although
closely related to halofantrine, does not appear to be car-
diotoxic at therapeutic doses [16], and the AL combina-
tion appears to have a favourable safety profile [17,18].
Recent studies of the safety of newer combination regi-
mens have been reassuring, identifying no serious con-
cerns, but to date, assessments of drug safety and
tolerability have been limited [19-22]. Most antimalarial
safety data have been gathered in clinical trials evaluating
treatment of single episodes of malaria. However, in prac-
tice, African children are treated for malaria repeatedly,
raising concern for toxicity resulting from repeated short-
term exposures [23]. The relatively small sample size of
clinical trials may also limit the ability to detect uncom-
mon events [24].
A longitudinal, single-blind, randomized controlled trial
assessing the efficacy and safety of AQ+SP, AS+AQ and AL
for all episodes of uncomplicated malaria was begun in
November 2004 in a cohort of children in Kampala,
Uganda [25]. An analysis of the efficacy data collected
through June 2006 indicated that the 28-day risks of
recurrent malaria differed significantly between the regi-
mens (26%, 17%, and 7% for the AQ+SP, AS+AQ, and AL
treatment groups, respectively) [25]. Here, detailed data
on the safety and tolerability of these therapies, in the
context of repeated treatments, is presented, with follow-
up extended through May 2007.
Methods
Study site and recruitment
The study was conducted between November 2004 and
May 2007 in the Mulago III parish of Kampala. Mulago III
parish is primarily residential with a high population den-
sity, typical of an urban slum. The parish is located near
the study clinic at Mulago Hospital, the main tertiary
referral hospital for Uganda.
A census project was conducted prior to the onset of the
study to generate a sampling frame of households with
appropriately aged children for recruitment and to gather
basic demographic information about the target popula-
tion [26]. Experienced home visitors approached house-
holds for recruitment sequentially from the randomized
list. If the parent/guardian(s) was interested in the study,
an appointment was made for a screening interview at our
study clinic. Enrollment occurred between November
2004 and April 2005. Study physicians recruited children
if they fulfilled all of the following eligibility criteria: 1)
age 1 to 10 years; 2) agreement to come to the study clinic
for any febrile episode or illness; 3) agreement to avoid
medications administered outside the study; 4) agree-
ment to remain in Kampala during the study period; 5) no
known side effects to the study medications; 6) weight ≥
10 kg; 7) absence of severe malnutrition; 8) absence of
known serious chronic disease; 9) absence of life threaten-
ing screening laboratory results; and 10) willingness of
parent or guardian to provide written informed consent.
The study received ethical approval from the Uganda
National Council of Science and Technology, the Mak-
erere University Research and Ethics Committee, and the
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University of California, San Francisco Committee on
Human Research.
Follow-up of study participants, malaria treatment 
allocation and administration
Parents and guardians were asked to bring participants to
the study clinic for all medical care. At each participant
encounter a standardized system was used to assess partic-
ipant symptoms, physical exam findings and laboratory
abnormalities based on grading of severity (normal, mild,
moderate, severe, life threatening). In general, events were
classified as mild if no therapy was required, as moderate
if minimal intervention and/or monitoring were required,
as severe if medical care and possible hospitalization were
required, and as life-threatening if active medical inter-
vention or hospitalization were required. Weakness, ano-
rexia, vomiting, diarrhoea, cough, pruritus, and coryza
were actively assessed in all participants. Headache,
abdominal pain, and nausea were also assessed in chil-
dren over three years of age. A standardized physical exam
was also conducted, which included assessment of hear-
ing and fine finger dexterity (ability to pick up a small
object). Any additional symptoms reported by the partic-
ipant or exam findings were also assessed and graded
accordingly.
If a participant presented with fever, a blood smear was
taken, and malaria diagnosed if any of the following crite-
ria were met: 1) complicated malaria (presence of severe
malaria or danger signs) and any parasitaemia; or 2) fever
(documented tympanic temperature ≥38.0°C and/or his-
tory of fever in the previous 24 hours) and any parasitae-
mia [25]. Following the diagnosis of their first episode of
uncomplicated malaria, study participants were randomly
assigned to receive one of three antimalarial regimens:
amodiaquine plus sulphadoxine-pyrimethamine
(AQ+SP), artesunate + amodiaquine (AS+AQ), or arte-
mether-lumefantrine (AL).
Study medications were administered according to
weight-based guidelines. The study medications were
dosed as follows: amodiaquine (Camoquin; Parke-Davis,
USA), 10 mg/kg on first two days then 5 mg/kg on third
day, sulphadoxine-pyrimethamine (Fansidar; Hoffman-
LaRoche, USA), sulphadoxine 25 mg/kg and pyrimeth-
amine 1.25 mg/kg as a single dose on first day; artesunate
(Arsumax; Sanofi-Aventis, France), 4 mg/kg on all three
days; artemether-lumefantrine (Coartem; Novartis, Swit-
zerland), 20/120 mg tablets given twice a day for three
days according to weight: 5–14 kg, one tablet per dose;
15–24 kg, two tablets per dose; and 25–34 kg, three tab-
lets per dose. Participants in the AQ+SP and AS+AQ
groups also received placebo tablets administered in the
evening over three days, dosed similarly to weight-based
guidelines for AL. Administration of each first daily dose
of medication was directly observed by the study nurses,
and each second daily dose of medication or placebo was
given to the participant's parent or guardian to administer
at home in the evening. All study personnel involved in
outcome assessment were blinded to treatment allocation
and participants were not informed of their treatment
assignments.
Adverse event monitoring
Participants randomized to treatment with study medica-
tions were assessed for adverse events beginning with the
first malaria episode. An adverse event was defined as any
untoward medical occurrence, irrespective of its suspected
relationship to the study medications as per International
Conference of Harmonization (ICH) guidelines [27]. A
serious adverse event was defined as any adverse experi-
ence that resulted in death, life threatening experience,
participant hospitalization, persistent or significant disa-
bility or incapacity, or specific medical or surgical inter-
vention to prevent serious outcome.
Active surveillance for adverse events
On the day that treatment was initiated (day 0), a baseline
assessment was conducted consisting of the standardized
history and physical examination, and laboratory testing
(complete blood count, measurement of alanine ami-
notransferase [ALT]). Participants were asked to return for
completion of treatment and standardized follow-up
assessment on days 1, 2, 3, 7, 14, or any other day they felt
ill. Complete blood count and ALT measurement were
repeated on day 14.
At each follow-up encounter, adverse events were identi-
fied by evaluating for any new or worsening symptoms,
physical exam findings, or laboratory abnormalities, as
compared to the day 0 baseline assessment. Participants
with abnormalities present on day 0 were not classified as
experiencing an adverse event unless the symptom wors-
ened from baseline, or resolved and then recurred. For
adverse events of moderate or greater severity, additional
information was captured, including the suspected rela-
tionship of the event to the study treatment (unrelated,
possible, probable, definite), event outcome, and date of
resolution. Participants who experienced a serious adverse
event were placed on study treatment hold until the rela-
tionship of the event to the study medications could be
established. If the event was deemed unrelated or only
possibly related to the study medications, participation in
the study was continued. Patients with clinical treatment
failure (according to 2006 WHO criteria) within 14 days
of initiation of therapy were treated with quinine, and
active surveillance for adverse events was continued for an
additional 14 days [3].
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Passive surveillance for adverse events
Following the initial 14-day period, participants were
asked to return to the clinic only when they desired med-
ical attention. Passive surveillance for adverse events of
moderate or greater severity continued until the partici-
pant was retreated with study medications, at which time
a new cycle of adverse event assessment and reporting
began, until the end of the study period, or until prema-
ture withdrawal from the study. Any case of symptomatic
malaria diagnosed more than 14 days after a previous epi-
sode was considered a new malaria episode (for treatment
purposes) and managed accordingly. Once randomized,
participants received the same treatment regimen for all
subsequent episodes of uncomplicated malaria.
Laboratory testing
Complete blood counts and alanine aminotransferase
measurements were performed by a College of American
Pathologists accredited laboratory using a Coulter AcT 5
diff CP (Beckman Coulter) for haematology tests and
Cobas Integra 400 plus (Roche) for chemistries.
Statistical analysis
Details on sample size calculation are presented elsewhere
[25]. Data were double-entered in Access (Microsoft Cor-
poration, Redmond, Wash), and statistical analysis was
performed using Stata version 8.0 (Stata Corporation,
College Station, TX, USA). Data were evaluated with an
intention-to-treat analysis including all participants with
uncomplicated malaria who were randomized to treat-
ment with study medications. Safety and tolerability out-
comes include risk of adverse events at 14 days (active
surveillance) and 42 days (passive surveillance) of follow-
up. Specific adverse events were limited to the first occur-
rence of an adverse event after each treatment with study
medications.
Data were analysed in a stepwise approach. All adverse
events of any severity or relationship at 14 days of follow-
up were first considered, then the analysis was restricted
for adverse events of moderate or greater severity, and
finally restricted for adverse events of possible, probable,
or definite relationship to study medications. Risks of
adverse events at 14 days were estimated using simple pro-
portions as nearly all patients completed 14 day follow-
up. Data at 42 days of follow-up was limited to adverse
events of moderate or greater severity. Risks of adverse
events at 42 days of follow-up were estimated using the
Kaplan-Meier product limit formula, censoring for partic-
ipants who did not complete 42 day follow-up either due
to repeat treatment with study drugs or premature with-
drawal from the study.
Pairwise comparisons of adverse events for individual epi-
sodes of malaria were made at 14 and 42 days of follow-
up with generalized estimating equations, adjusting for
repeated measures in the same study participant using
exchangeable correlation and robust standard errors. A p-
value of < 0.05 was considered statistically significant.
Results
Study population
Details of recruitment and the study population are pre-
sented elsewhere [25,26]. Briefly, of 743 children
screened, 142 were excluded from the study. The most
common reasons for exclusion during screening included:
parent/guardian unwilling to provide informed consent
(30%), plans to move out of Kampala (20%), and weight
< 10 kg (19%). A total of 601 children were enrolled from
323 households. Of these, 382 were diagnosed with at
least one episode of uncomplicated malaria over the
period of follow-up and were randomized to one of the
three treatment groups (Figure 1).
Study treatment follow-up
A total of 1120 study treatments were administered dur-
ing 605 person-years of follow-up (Figure 1). The median
number of treatments administered per participant
treated at least once with study medications was 4 (range
1–20). The median age of participants receiving study
treatments was 6.3 years (range 1.1 – 12.3 years), and was
similar between the treatment arms. Nearly all (98%) par-
ticipants completed 14 day follow-up for assessment of
adverse events. Most participants (80%) completed 42
day follow-up; of the remaining participants, follow-up
for 19% ended before 42 days when they were retreated
with study medications, and 1% were prematurely with-
drawn from the study. Reasons for premature withdrawal
included movement out of the study area (8 participants),
loss to follow-up (2), non-compliance (1), and with-
drawal of consent (1).
Risk of adverse events at 14 days
During the first 14 days after therapy, a total of 2496
adverse events, defined as any untoward medical occur-
rence, irrespective of suspected relationship to study med-
ications, were detected. Most events were mild; only 749
(30%) were of moderate or greater severity. Of these
events, 143 (19%) were classified as not related, 541
(72%) as possibly related, and 65 (9%) as probably
related to study medications. No adverse events were con-
sidered to be definitely related to the study medications.
Statistically significant differences between the treatment
groups were found for 4 adverse events: anorexia, subjec-
tive fever, weakness, and elevated temperature (Table 1).
Within the first 14 days, participants treated with AQ+SP
had a greater risk, compared to those treated with AL, of
anorexia, weakness, and subjective fever, and a greater
risk, compared to those treated with AS+AQ, of weakness
Malaria Journal 2008, 7:106 http://www.malariajournal.com/content/7/1/106
Page 5 of 11
(page number not for citation purposes)
and subjective fever. Participants treated with AL had a
higher risk of elevated temperature than those receiving
AS+AQ.
Laboratory tests at 14 days
At 14 days, there were no statistically significant differ-
ences in the risk of laboratory-related adverse events
between treatment groups (Table 1). However, notewor-
thy abnormalities in neutrophil counts were repeatedly
observed in one subject. This participant, randomized to
AS+AQ, experienced neutropaenia after six of 10 treat-
ments; four episodes were of mild severity (750–1200
cells/mm3), one was moderate (660 cells/mm3), and one
was severe (330 cells/mm3). For nine of the 10 treatments,
the initial day 0 neutrophil count was within normal lim-
its. All episodes of neutropaenia resolved spontaneously.
The participant was subsequently excluded from the study
due to concern about a causal association between AS+AQ
Trial ProfileFigure 1
Trial Profile.
601 children enrolled
382 children randomized to
study treatment
129 children randomized
to receive AQ+SP
133 children randomized
to receive AS+AQ
120 children randomized
to receive AL
362 Treatments
Per participant
  44 received 1 treatment
  22 received 2 treatments
  54 received > 3 treatments
362 Treatments
Per participant
  57 received 1 treatment
  28 received 2 treatments
  48 received > 3 treatments
396 Treatments
Per participant
  37 received 1 treatment
  36 received 2 treatments
  56 received > 3 treatments
14 Day follow-up
389 completed follow-up
   7   lost to follow-up
929 total adverse events
14 Day follow-up
359 completed follow-up
   6  lost to follow-up
791 total adverse events
14 Day follow-up
355 completed follow-up
   7  lost to follow-up
776 total adverse events
42 Day follow-up
296 completed follow-up
100 incomplete follow-up
  95 with repeat treatment
    5 prematurely withdrawn
1052 total adverse events
42 Day follow-up
292 completed follow-up
  70 incomplete follow-up
67 with repeat treatment
  3 prematurely withdrawn
934 total adverse events
42 Day follow-up
312 completed follow-up
  50 incomplete follow-up
46 with repeat treatment
  4 prematurely withdrawn
950 total adverse events
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and the neutropaenic episodes. Moderate grade neutro-
paenia was only seen in one other participant, after treat-
ment with AQ+SP. This participant developed
neutropaenic episodes after two of 15 study treatments,
with one mild, and one moderate decrease in neutrophil
count.
Serious adverse events at 14 days
A total of 15 serious adverse events (SAEs) occurred
within the first 14 days of follow-up (Table 1). Convul-
sions were most commonly reported, with eight episodes
occurring in as many participants, all below seven years of
age. The majority of the convulsions (75%) occurred in
association with fever, and seven were classified as possi-
bly related to study medications. One participant with a
non-febrile convulsion was later found to have epilepsy,
and in another case a complete history was not available.
Two participants treated with AQ+SP developed signifi-
cant weakness possibly related to study medications.
Another two participants had bronchopneumonia requir-
ing inpatient hospitalization. Additional serious events
included severe vomiting, ALT elevation (thought to be an
infectious hepatitis), and a traumatic bone fracture. No
serious adverse event was considered to be probably or
definitely related to study medications, and no deaths
occurred.
Risk of adverse events (of moderate or greater severity) at 
14 days
To focus on clinically relevant adverse events occurring
within the first 14 days of follow-up, the risk of develop-
ing events of moderate or greater severity was analysed
(Table 2). Although the risks of more severe events were
lower, the comparative differences between the treatment
groups were similar. Nearly all of the previously described
differences for risk of anorexia, weakness, subjective fever,
and elevated temperature remained significant, and the
associations strengthened. Further restricting the analysis,
by focusing on events of moderate or greater severity
which were possibly or probably related to study treat-
ment, provided similar results.
There were no statistically significant differences in labo-
ratory abnormalities of moderate or greater severity
Table 1: Risk (%) of adverse events associated with study treatment within the first 14 days of treatment, including events of any 
severity grade
AQ+SP (n = 396) AS+AQ (n = 362) AL (n = 362)
Signs and symptoms
Coryza 115 (29.0%) 125 (34.5%) 118 (32.6%)
Cough 119 (30.1%) 108 (29.8%) 117 (32.3%)
Anorexia* 115 (29.0%) 89 (24.6%) 67 (18.5%)
Weakness† 93 (23.5%) 58 (16.0%) 47 (13.0%)
Abdominal pain 77 (19.4%) 56 (15.5%) 63 (17.4%)
Vomiting 64 (16.2%) 49 (13.5%) 41 (11.3%)
Subjective fever‡ 59 (14.9%) 31 (8.6%) 33 (9.1%)
Headache 45 (11.3%) 38 (10.5%) 50 (13.8%)
Rash 38 (9.6%) 43 (11.9%) 46 (12.7%)
Generalized pruritus 34 (8.6%) 39 (10.8%) 30 (8.3%)
Diarrhoea 34 (8.6%) 29 (8.0%) 31 (8.6%)
Elevated temperatureγ 20 (5.1%) 14 (3.9%) 31 (8.6%)
Nausea 12 (3.0%) 14 (3.9%) 13 (3.6%)
Hepatosplenomegaly 6 (1.5%) 9 (2.5%) 4 (1.1%)
Laboratory abnormalities**
Neutropaenia 27/381 (7.1%) 18/345 (5.2%) 13/343 (3.8%)
Anaemia 9/393 (2.3%) 20/356 (5.6%) 11/357 (3.1%)
Elevated ALT 2/392 (0.5%) 1/358 (0.3%) 2/357 (0.6%)
Thrombocytopaenia 1/389 (0.3%) 0/350 0/351
Serious adverse events 7 (1.8%) 4 (1.1%) 4 (1.1%)
* Anorexia: AQ+SP vs. AL, p = 0.001
† Weakness: AQ+SP vs. AS+AQ, p = 0.015; AQ+SP vs. AL, p < 0.001
‡ Subjective Fever: AQ+SP vs. AS+AQ, p = 0.010; AQ+SP vs AL, p = 0.017
γ Elevated Temperature: AL vs. AS+AQ, p = 0.013
** Laboratory data not available on all participants
Malaria Journal 2008, 7:106 http://www.malariajournal.com/content/7/1/106
Page 7 of 11
(page number not for citation purposes)
between study treatments. There were three episodes of
moderate or severe neutropaenia (described above), 10
episodes of moderate or severe anaemia, and one episode
of severe thrombocytopaenia. One participant treated
with AL developed severe ALT elevation at 14 days of fol-
low-up, which was deemed possibly related to study med-
ications, although an infectious hepatitis was suspected.
Factors associated with adverse events
We assessed for factors which might modify the effect
between treatment and risk of adverse events. Neither the
number of prior treatments, nor duration since prior treat-
ment, significantly impacted the risk of adverse events.
However, when the analysis of the association between
treatment and risk of adverse events was stratified by age,
Table 2: Risk (%) of adverse events (of moderate or greater severity) associated with study treatment within the first 14 days of 
treatment
AQ+SP (n = 396) AS+AQ (n = 362) AL (n = 362)
Signs and symptoms
Coryza 18 (4.6%) 29 (8.0%) 21 (5.8%)
Cough 30 (7.6%) 45 (12.4%) 37 (10.2%)
Anorexia* 39 (9.9%) 24 (6.6%) 15 (4.1%)
Weakness† 37 (9.3%) 20 (5.5%) 9 (2.5%)
Abdominal pain 11 (2.8%) 8 (2.2%) 6 (1.7%)
Vomiting 15 (3.8%) 5 (1.4%) 7 (1.9%)
Subjective fever‡ 59 (14.9%) 31 (8.6%) 33 (9.1%)
Headache 2 (0.5%) 5 (1.38%) 4 (1.1%)
Rash 15 (3.8%) 10 (2.8%) 11 (3.0%)
Generalized pruritus 21 (5.3%) 19 (5.3%) 16 (4.4%)
Diarrhoea 0 4 (1.1%) 5 (1.4%)
Elevated temperatureγ 14 (3.5%) 8 (2.2%) 23 (6.4%)
Nausea 4 (1.0%) 1 (0.3%) 1 (0.3%)
Hepatosplenomegaly 1 (0.3%) 1 (0.3%) 1 (0.3%)
Laboratory abnormalities**
Neutropaenia 1/381(0.3%) 2/345 (0.6%) 0/343
Anaemia 4/393 (1.0%) 5/356 (1.4%) 1/357 (0.3%)
Elevated ALT 0/392 0/358 1/357 (0.3%)
Thrombocytopaenia 1/389 (0.3%) 0/350 0/351
* Anorexia: AQ+SP vs. AL, p = 0.004
† Weakness: AQ+SP vs. AL, p < 0.001
‡ Subjective Fever: AQ+SP vs. AS+AQ, p = 0.010; AQ+SP vs AL, p = 0.017
γ Elevated Temperature: AL vs. AS+AQ, p = 0.007
** Laboratory data not available on all participants
Table 3: Association between study treatment and adverse events (of moderate or greater severity) within the first 14 days of 
treatment, stratified by age group
Adverse events Comparison groups Age < 5 years Age ≥ 5 years
RR (95% CI) p-value RR (95% CI) p-value
Anorexia AQ+SP vs. AL 3.82 (1.59–9.17) 0.003 1.73 (0.79–3.81) 0.17
AQ+SP vs. AS+AQ 2.10 (1.04–4.23) 0.04 1.32 (0.64–2.71) 0.46
Weakness AQ+SP vs. AL 5.40 (1.86–15.7) 0.002 3.08 (1.17–8.14) 0.02
AQ+SP vs. AS+AQ 2.26 (1.01–5.05) 0.04 1.68 (0.76–3.69) 0.20
Subjective fever AQ+SP vs. AL 1.55 (0.78–3.10) 0.21 1.78 (1.08–2.93) 0.02
AQ+SP vs. AS+AQ 1.22 (0.64–2.31) 0.54 2.80 (1.53–5.12) 0.001
Elevated temperature AL vs. AQ+SP or AS+AQ 1.34 (0.60–3.03) 0.47 3.66 (1.59–8.41) 0.002
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significant differences were found (Table 3). The associa-
tion between treatment with AQ+SP and anorexia or
weakness was primarily seen in younger children; while
the association between AQ+SP treatment and subjective
fever, and AL treatment and elevated temperature was
observed in older children. For young children, the risk of
anorexia associated with AQ+SP treatment was nearly four
times higher than with AL, and two times higher than with
AS+AQ. Similarly, the risk of weakness for young children
treated with AQ+SP was over five times higher than for
those treated with AL, and over two times higher than for
AS+AQ-treated children.
Risk of adverse events at 42 days
Passive surveillance for adverse events of moderate or
greater severity continued until participants were diag-
nosed with another episode of uncomplicated malaria, or
study follow-up ended. During 15–42 days of follow-up
after study medication treatment, an additional 440
adverse events were recorded, representing 15% of total
adverse events captured. No life-threatening adverse
events were observed. No events suspected to be probably
or definitely related to study medications were detected.
During 15–42 days of follow-up, an additional three SAEs
were reported. Of these, one event was a febrile convul-
sion; another was elevation of liver enzymes secondary to
acute hepatitis A infection, and the last a skin abscess.
At 42 days, patients treated with AQ+SP remained at sig-
nificantly higher risk of anorexia and weakness than AL-
treated participants; however, the difference in risk of sub-
jective fever was not sustained (Table 4). AL treatment
remained associated with a higher risk of elevated temper-
ature as compared to treatment with AS+AQ and AQ+SP.
In addition, a difference in the risk of diarrhoea emerged
in the 42-day analysis, with a higher risk of diarrhoea
associated with AL than AQ+SP treatment (p = 0.021).
Discussion
In this randomized, blinded, longitudinal clinical trial,
the safety and tolerability of three commonly used anti-
malarial combinations in Ugandan children was evalu-
ated. Although all three regimens were found to be safe,
participants treated with AQ+SP, particularly young chil-
dren, were significantly more likely to develop anorexia
and weakness than participants treated with AL or AS+AQ.
Focusing the analysis on events of moderate or greater
severity strengthened the observed associations, but rede-
fining outcomes based on suspected relationship to study
medications was of limited utility. Extending follow-up
for adverse events from 14 to 42 days had little impact on
the findings. Overall, in our cohort of children in Kam-
pala, AL and AS+AQ appear to be superior to AQ+SP due
to improved tolerability and greater efficacy [25].
ACTs are generally considered to be safe and well-toler-
ated, which is supported by this study [17,28,29]. The
finding that participants treated with AL were more likely
to have elevated temperature may be due to the known
anti-pyretic properties of amodiaquine, which was a com-
ponent of the other two study regimens. Persisting fever
after treatment with AL could contribute to the perception
that the combination is not as effective as other regimens,
which may need to be addressed in training of health care
workers and community sensitization. The higher risk of
diarrhoea observed in AL-treated patients in the 42-day
Table 4: Risk (%) of adverse events (of moderate or greater severity) associated with study treatment within the first 42 days of 
treatmentΔ
Adverse events AQ+SP (n = 396) AS+AQ (n = 362) AL (n = 362)
Coryza 10.0% 12.2% 13.1%
Cough 14.7% 22.8% 20.9%
Anorexia* 10.3% 9.7% 5.5%
Weakness† 9.7% 6.5% 3.1%
Abdominal pain 6.0% 3.3% 3.4%
Vomiting 3.8% 1.7% 1.9%
Subjective fever 24.9% 22.8% 24.2%
Headache 1.5% 2.8% 3.4%
Rash 6.0% 5.5% 4.7%
Generalized pruritus 7.4% 8.2% 6.5%
Diarrhoea‡ 0.7% 1.1% 3.2%
Elevated temperatureγ 4.8% 4.5% 9.2%
Nausea 1.0% 0.3% 0.3%
Hepatosplenomegaly 0.3% 0.3% 0.3%
ΔRisk estimated by Kaplan-Meier product limit formula
* Anorexia: AQ+SP vs. AL, p = 0.005
† Weakness: AQ+SP vs. AL, p < 0.001
‡ Diarrhoea: AL vs. AQ+SP, p = 0.021
γ Elevated Temperature: AL vs. AQ+SP, p = 0.029; AL vs. AS+AQ, p = 0.008
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analysis has previously been reported, although it is
unclear why the onset of this adverse event was delayed
[30,31].
Although no significant differences in safety were found
between AS+AQ and AL in the cohort, the one case of
repeated neutropaenic episodes associated with AS+AQ
was concerning given the known propensity of amodi-
aquine to cause blood dyscrasias and agranulocytosis [8].
A recent study in Uganda found a significantly increased
risk of moderate and severe neutropaenia in HIV-infected
children (also receiving co-trimoxazole prophylaxis and
antiretroviral therapy) who were treated with AS+AQ, rais-
ing concern about use of AS+AQ for the treatment of
malaria in HIV-infected individuals [32]. As newer ACTs
are developed for the treatment of malaria, continued
evaluation of the safety and tolerability of these combina-
tion therapies in clinical trials will be important.
In this study, a higher risk of anorexia and weakness asso-
ciated with AQ+SP when compared with the other regi-
mens was found, consistent with prior reports of severe
weakness in Rwandan children treated with AQ+SP
[20,28]. However, our findings suggest that the tolerabil-
ity of AQ+SP may be age-dependent, with younger chil-
dren significantly more likely to experience anorexia and
weakness when treated with AQ+SP than with the ACT
regimens. The finding that AQ+SP was associated with a
higher risk of subjective fever in older children may reflect
imprecision in obtaining a history of fever. Older children
may have reported an overall syndrome of "feeling
unwell", including subjective fever, while caregivers of
younger children may have only reported the presence of
subjective fever if the child felt hot. Although differences
in the tolerability between AQ+SP and ACTs were found,
no significant differences in the safety of these regimens
were seen. In East Africa, where recent studies have also
raised concerns about the effectiveness of AQ+SP, ACTs
are now preferable [20,25,33]. However, in regions of
Africa where both drugs remain effective and/or AQ+SP
has been shown to have superior efficacy, the optimal
choice for first-line treatment will need to be made con-
sidering all relevant factors, including efficacy, safety and
tolerability, cost, and availability [6,34].
No standardized system for adverse event monitoring in
antimalarial clinical trials currently exists, and the
approach to monitoring may differ between sites. Guide-
lines for use of laboratory testing in antimalarial drug
safety monitoring are also lacking.  In this study, events
were actively assessed at all follow-up visits, with inter-
views, a standard physical exam, and laboratory tests at
standard intervals. Although time intensive, the system
allowed events related to drug tolerability, such as ano-
rexia and weakness, to be captured. Relying on spontane-
ous reporting of symptoms by participants, or assessing
only for objective measures, such as serious adverse events
and laboratory abnormalities, may have missed differ-
ences in tolerability. The duration of follow-up for moni-
toring of adverse events after antimalarial therapy is
variable, often coinciding with the recommended length
of follow-up for efficacy outcomes of 28 or 42 days
[17,19,20,28]. Few differences in the comparative risk of
adverse events at 14 and 42 days of follow-up were found.
All study medications were safe at 14 days of follow-up,
and, except for the emergence of a risk of diarrhoea in par-
ticipants treated with AL, extending the follow-up period
to 42 days did not identify any changes in safety, or toler-
ability compared to 14-day outcomes.
There were several potential limitations to this study.
Although the assessment of adverse events was designed
to be as objective as possible by using grading scales for
severity and relationship, the results are limited by the
subjective interpretations of symptom reports. In addi-
tion, active surveillance continued only for the 14 days
after study treatment was initiated. Extending the dura-
tion of active surveillance may have captured additional
events of interest. Laboratory values were only assessed at
day 0 and day 14 of study treatment, routinely every 90
days, and at the discretion of the study clinicians. Some
abnormalities may not have been captured by this sched-
ule. Although 382 patients treated with study medications
over multiple treatments were followed, the relatively
small sample size limited the ability to detect uncommon
events. Finally, multiple comparisons in the risk of
adverse events associated with treatment groups were
made, increasing the likelihood that statistically signifi-
cant differences in risks could have been detected just by
chance.
Conclusion
This study confirms the safety and tolerability of AS+AQ
and AL in Ugandan children, and suggests that AQ+SP is
safe, but less well-tolerated than the other regimens, par-
ticularly in young children. The higher risk of elevated
temperature observed in association with AL could impact
on the perception of its effectiveness and may need to be
addressed. Although no significant differences in safety
were found between AS+AQ and AL, the one case of
repeated neutropaenic episodes associated with AS+AQ
was concerning. As newer ACTs are deployed, evaluating
for safety and comparative tolerability will be essential.
Standardized guidelines for monitoring adverse events in
antimalarial clinical trials are needed.
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